Intraperitoneal Delivery of Human Natural Killer Cells for Treatment of Ovarian Cancer in a Mouse Xenograft Model

Overview

Journal Cytotherapy

Publisher Elsevier

Specialties Cell Biology
Pharmacology

Date 2013 Sep 3

PMID 23993303

Citations 41

Authors

Melissa A Geller

David A Knorr

David A Hermanson

Lee Pribyl

Laura Bendzick

Valarie McCullar

Jeffrey S Miller

Dan S Kaufman

Affiliations

Soon will be listed here.

Abstract

Background Aims: There is an urgent need for novel therapeutic strategies for relapsed ovarian cancer. Dramatic clinical anti-tumor effects have been observed with interleukin (IL)-2 activated natural killer (NK) cells; however, intravenous delivery of NK cells in patients with ovarian cancer has not been successful in ameliorating disease. We investigated in vivo engraftment of intraperitoneally (IP) delivered NK cells in an ovarian cancer xenograft model to determine if delivery mode can affect tumor cell killing and circumvent lack of NK cell expansion.

Methods: An ovarian cancer xenograft mouse model was established to evaluate efficacy of IP-delivered NK cells. Tumor burden was monitored by bioluminescent imaging of luciferase-expressing ovarian cancer cells. NK cell persistence, tumor burden and NK cell trafficking were evaluated. Transplanted NK cells were evaluated by flow cytometry and cytotoxicity assays.

Results: IP delivery of human NK cells plus cytokines led to high levels of circulating NK and was effective in clearing intraperitoneal ovarian cancer burden in xenografted mice. NK cells remained within the peritoneal cavity 54 days after injection and had markers of maturation. Additionally, surviving NK cells were able to kill ovarian cancer cells at a rate similar to pre-infusion levels, supporting that in vivo functionality of human NK cells can be maintained after IP infusion.

Conclusions: IP delivery of NK cells leads to stable engraftment and antitumor response in an ovarian cancer xenograft model. These data support further pre-clinical and clinical evaluation of IP delivery of allogeneic NK cells in ovarian cancer.

Citing Articles

Innovative landscapes in intraperitoneal therapy of ovarian cancer.

Kumar K, Madhusoodanan M, Pangath M, Menon D Drug Deliv Transl Res. 2025; .

PMID: 39888579 DOI: 10.1007/s13346-024-01765-w.

C/EBPβ-dependent autophagy inhibition hinders NK cell function in cancer.

Portale F, Carriero R, Iovino M, Kunderfranco P, Pandini M, Marelli G Nat Commun. 2024; 15(1):10343.

PMID: 39609420 PMC: 11604937. DOI: 10.1038/s41467-024-54355-2.

Combinatorial immunotherapy of anti-MCAM CAR-modified expanded natural killer cells and NKTR-255 against neuroblastoma.

Luo W, Gardenswartz A, Hoang H, Chu Y, Tian M, Liao Y Mol Ther Oncol. 2024; 32(4):200894.

PMID: 39554906 PMC: 11567912. DOI: 10.1016/j.omton.2024.200894.

NK cell line modified to express a potent, DR5 specific variant of TRAIL, show enhanced cytotoxicity in ovarian cancer models.

Sheedy A, Burduli N, Prakash A, Gurney M, Hanley S, Prendeville H Heliyon. 2024; 10(15):e34976.

PMID: 39170449 PMC: 11336271. DOI: 10.1016/j.heliyon.2024.e34976.

Exploring the Potential of Natural Killer Cell-Based Immunotherapy in Targeting High-Grade Serous Ovarian Carcinomas.

Kaur K, Sanghu J, Memarzadeh S, Jewett A Vaccines (Basel). 2024; 12(6).

PMID: 38932405 PMC: 11209217. DOI: 10.3390/vaccines12060677.

References

Ndhlovu L, Lopez-Verges S, Barbour J, Jones R, Jha A, Long B . Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood. 2012; 119(16):3734-43. PMC: 3335380. DOI: 10.1182/blood-2011-11-392951. View

Waldmann T, Lugli E, Roederer M, Perera L, Smedley J, MacAllister R . Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood. 2011; 117(18):4787-95. PMC: 3100690. DOI: 10.1182/blood-2010-10-311456. View

Huenecke S, Zimmermann S, Kloess S, Esser R, Brinkmann A, Tramsen L . IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion. J Immunother. 2010; 33(2):200-10. DOI: 10.1097/CJI.0b013e3181bb46f7. View

Denman C, Senyukov V, Somanchi S, Phatarpekar P, Kopp L, Johnson J . Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One. 2012; 7(1):e30264. PMC: 3261192. DOI: 10.1371/journal.pone.0030264. View

Berg M, Lundqvist A, McCoy Jr P, Samsel L, Fan Y, Tawab A . Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy. 2009; 11(3):341-55. PMC: 2736058. DOI: 10.1080/14653240902807034. View

Tian X, Hexum M, Penchev V, Taylor R, Shultz L, Kaufman D . Bioluminescent imaging demonstrates that transplanted human embryonic stem cell-derived CD34(+) cells preferentially develop into endothelial cells. Stem Cells. 2009; 27(11):2675-85. PMC: 2857550. DOI: 10.1002/stem.204. View

Barao I, Hanash A, Hallett W, Welniak L, Sun K, Redelman D . Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. Proc Natl Acad Sci U S A. 2006; 103(14):5460-5. PMC: 1459377. DOI: 10.1073/pnas.0509249103. View

Skak K, Frederiksen K, Lundsgaard D . Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology. 2007; 123(4):575-83. PMC: 2433320. DOI: 10.1111/j.1365-2567.2007.02730.x. View

Judson P, Geller M, Bliss R, Boente M, Downs Jr L, Argenta P . Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer. Gynecol Oncol. 2003; 91(2):389-94. DOI: 10.1016/j.ygyno.2003.08.004. View

10.

Gruenbacher G, Gander H, Nussbaumer O, Nussbaumer W, Rahm A, Thurnher M . IL-2 costimulation enables statin-mediated activation of human NK cells, preferentially through a mechanism involving CD56+ dendritic cells. Cancer Res. 2010; 70(23):9611-20. DOI: 10.1158/0008-5472.CAN-10-1968. View

11.

Ljunggren H, Malmberg K . Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 2007; 7(5):329-39. DOI: 10.1038/nri2073. View

12.

Lopez-Verges S, Milush J, Pandey S, York V, Arakawa-Hoyt J, Pircher H . CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood. 2010; 116(19):3865-74. PMC: 2981540. DOI: 10.1182/blood-2010-04-282301. View

13.

Miller J, Soignier Y, Panoskaltsis-Mortari A, McNearney S, Yun G, Fautsch S . Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005; 105(8):3051-7. DOI: 10.1182/blood-2004-07-2974. View

14.

Kappos L, Radue E, OConnor P, Polman C, Hohlfeld R, Calabresi P . A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362(5):387-401. DOI: 10.1056/NEJMoa0909494. View

15.

Sutlu T, Alici E . Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med. 2009; 266(2):154-81. DOI: 10.1111/j.1365-2796.2009.02121.x. View

16.

Carlsten M, Bjorkstrom N, Norell H, Bryceson Y, van Hall T, Baumann B . DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 2007; 67(3):1317-25. DOI: 10.1158/0008-5472.CAN-06-2264. View

17.

Armstrong D . Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist. 2002; 7 Suppl 5:20-8. DOI: 10.1634/theoncologist.7-suppl_5-20. View

18.

Cooper M, Elliott J, Keyel P, Yang L, Carrero J, Yokoyama W . Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A. 2009; 106(6):1915-9. PMC: 2644138. DOI: 10.1073/pnas.0813192106. View

19.

Liao S, Liu J, Lin P, Shi T, Jain R, Xu L . TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models. Clin Cancer Res. 2011; 17(6):1415-24. PMC: 3060297. DOI: 10.1158/1078-0432.CCR-10-2429. View

20.

McCullar V, Oostendorp R, Panoskaltsis-Mortari A, Yun G, Lutz C, Wagner J . Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15. Exp Hematol. 2008; 36(5):598-608. PMC: 2390774. DOI: 10.1016/j.exphem.2008.01.001. View